Atossa | GenomeWeb

Atossa

NEW YORK (GenomeWeb) – Atossa Genetics announced today that its subsidiary, the National Reference Laboratory for Breast Health, and BioVentive have reached a deal to market and promote NRLBH's services.

Atossa Genetics announced the hiring of Jelle Kylstra as its new VP of clinical research and development. Kylstra joined the company on May 19, and brings with her more than 23 years of industry experience.

NEW YORK (GenomeWeb News) – Atossa Genetics said after the close of the market on Thursday that its full-year 2013 revenues grew 31 percent year over year on increased product sales.

NEW YORK (GenomeWeb News) – Atossa Genetics today priced its public offering of 5.8 million units at $2.40 per unit, saying it anticipates raising $14 million in gross proceeds.

NEW YORK (GenomeWeb News) – Atossa Genetics said on Tuesday that it has submitted a premarket 510(k) notification with the US Food and Drug Administration for its ForeCYTE breast cancer test device.

NEW YORK (GenomeWeb News) – Atossa Genetics has filed a shelf registration to potentially offer from time to time up to $40 million in securities.

NEW YORK (GenomeWeb News) – Atossa Genetics reported on Tuesday that revenues in its third quarter dropped 27 percent year over year.
It also said it inked a new deal with Aspire Capital for the sale of up to $25 million in common stock during the next 30 months.

NEW YORK (GenomeWeb News) – A class action lawsuit has been filed in federal court alleging Atossa Genetics violated federal securities laws.

NEW YORK (GenomeWeb News) – Atossa Genetics on Friday voluntarily recalled its ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology (MASCT) Test device from the market in the wake of concerns raised by the US Food and Drug Administration.

NEW YORK (GenomeWeb News) – Atossa Genetics today said that McKesson Medical-Surgical will distribute and sell the firm's MASCT device and patient collection kits.

Pages

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.